AI-Powered scans aim to predict breast cancer remission without surgery

NCT ID NCT06708910

Recruiting now Diagnosis Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether a special type of scan (PET/MRI) combined with artificial intelligence can accurately tell if HER2-positive breast cancer has been completely eliminated after chemotherapy. Researchers will scan 460 women before, during, and after treatment, then compare the scan results with tissue samples taken during routine surgery. The goal is to see if the scan can reliably identify complete remission, potentially replacing some follow-up procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-FDG PET/MRI with artificial intelligence
What this could lead to: If successful, this could provide a non-invasive way to accurately assess treatment response in HER2-positive breast cancer, reducing the need for surgical biopsies.
What could go wrong: This is an observational study, not a treatment trial. The AI model may not be accurate enough in real-world settings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CARCINOMA

Contacts and locations

Locations

Department of Diagnostic and Interventional Radiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
RECRUITING

Düsseldorf, North Rhine-Westphalia, 40225, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.